(Total Views: 533)
Posted On: 01/21/2021 10:50:56 PM
Post# of 155038
Some institutional investors have already researched leronlimab's history and potential, but most probably have not. Our share price suspiciously appears to be stable at $5.00 which is a red line for most big investors.
An EUA and/or uplisting will get the attention of these bigger investors, and when their reseach takes them to leronlimab's history against covid-19 and then to all the other diseases and trials, it will get exciting.
Can't imagine buying say 50,000 shares at under a dollar, that wasn't me.
I am diversified as I've said before, I bought CYDY at 8 different share prices, all above $3.00
An EUA and/or uplisting will get the attention of these bigger investors, and when their reseach takes them to leronlimab's history against covid-19 and then to all the other diseases and trials, it will get exciting.
Can't imagine buying say 50,000 shares at under a dollar, that wasn't me.
I am diversified as I've said before, I bought CYDY at 8 different share prices, all above $3.00
(1)
(0)
